{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:21:35Z","timestamp":1740165695457,"version":"3.37.3"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Canc Conf J"],"DOI":"10.1007\/s13691-024-00694-2","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T10:02:49Z","timestamp":1719482569000},"page":"387-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of selpercatinib treatment for anaplastic thyroid carcinoma resulting in abscess formation"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5184-9966","authenticated-orcid":false,"given":"Ryo","family":"Kuboki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yagihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Asakage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"issue":"3","key":"694_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","volume":"15","author":"A Drilon","year":"2018","unstructured":"Drilon A, Hu ZI, Lai GGY et al (2018) Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 15(3):151\u2013167","journal-title":"Nat Rev Clin Oncol"},{"key":"694_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B et al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383:825\u2013835","journal-title":"N Engl J Med"},{"issue":"9","key":"694_CR3","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1089\/thy.2019.0477","volume":"30","author":"D Dias-Santagata","year":"2020","unstructured":"Dias-Santagata D, Lennerz JK, Sadow PM et al (2020) Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma. Thyroid 30(9):1384\u20131389","journal-title":"Thyroid"},{"key":"694_CR4","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00268-012-1437-z","volume":"36","author":"I Sugitani","year":"2012","unstructured":"Sugitani I, Miyauchi A, Suhino K et al (2012) Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort study of 677 patients. World J Surg 36:1247\u20131254","journal-title":"World J Surg"},{"key":"694_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/cancers11070943","volume":"11","author":"J Ljubas","year":"2019","unstructured":"Ljubas J, Ovesen T, Rusan M (2019) Systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer. Cancers 11:943","journal-title":"Cancers"},{"key":"694_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"Tahara M, Kiyota N, Yamazaki T et al (2017) Lenvatinib for anaplastic thyroid cancer. Front Oncol 7:25","journal-title":"Front Oncol"},{"key":"694_CR7","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","volume":"17","author":"JE Chaft","year":"2011","unstructured":"Chaft JE, Oxnard GR, Sima CS et al (2011) Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to Erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 17:6298\u20136303","journal-title":"Clin Cancer Res"}],"container-title":["International Cancer Conference Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-024-00694-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13691-024-00694-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-024-00694-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:26:35Z","timestamp":1728505595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13691-024-00694-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":7,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s13691-024-00694-2","relation":{},"ISSN":["2192-3183"],"issn-type":[{"type":"electronic","value":"2192-3183"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"16 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}